Nirsevimab shows 90% success in shielding infants from RSV hospitalizations

Study demonstrated a 90% effectiveness of nirsevimab in preventing RSV-associated hospitalizations in infants, with a significant finding being the timely vaccination’s role in offering protection.

Is AI Failing Drug Development? The Unseen Challenges

Noam Solomon, CEO at Immunai For over a decade, we’ve heard about AI’s transformative potential in therapeutics (Tx), but where’s the evidence? Has it all

January 16, 2025

How Special Olympics kickstarted the push for better disability data

On July 1st, 1995, the world’s spotlight shone upon Yale’s football stadium in New Haven, Connecticut. It was the latest Special Olympics World Games, and

September 25, 2024

Selecta Biosciences is narrowing its focus

Selecta Biosciences announced Thursday that it will stop investment in most of its pipeline assets except for a treatment for chronic refractory gout licensed to

August 18, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.